Clinical trials: Neoplasm, Oral
Acute Myeloid Leukemia (AML)
A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy
This study will be conducted in two parts. Part 1 will be the Dose Confirmation portion to determine recommended Phase 3 dose (RPTD) of venetoclax in combination with azacitidine (AZA).
- Trial name
- VIALE-M (NCT04102020)
- Testing
- Venetoclax, Azacitidine
- Where
- 156 sites in United States, Australia and 17 more
- Volunteers
- 112 people
- Sponsor
- AbbVie
Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma
Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy
This phase II trial studies how well giving temsirolimus together with cetuximab works compared to temsirolimus alone in treating patients with recurrent and/or metastatic head and neck cancer who did not respond to previous…
- Conditions
- Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Laryngeal Verrucous Carcinoma, Recurrent Lip and Oral Cavity Squamous Cell Carcinoma
- Trial name
- MAESTRO HN (NCT01256385)
- Testing
- Cetuximab, Laboratory Biomarker Analysis, Temsirolimus
- Where
- 24 sites in United States, China
- Volunteers
- 86 people
- Sponsor
- National Cancer Institute (NCI)
Lip, Oral Cavity Squamous Cell Carcinoma
Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck
This phase II trial studies how well nivolumab works, with or without BMS986205, in treating patients with stage II-IV squamous cell cancer of the head and neck.
- Conditions
- Lip, Oral Cavity Squamous Cell Carcinoma, Pharynx, Larynx
- Trial name
- NCT03854032
- Testing
- Nivolumab, IDO1 Inhibitor BMS-986205, Therapeutic Conventional Surgery
- Where
- 2 sites in United States
- Volunteers
- 65 people
- Sponsor
- Thomas Jefferson University
Dysphagia, Head and Neck Cancer
Chemo/XRT +/- Amifostine to Assess Outcomes Related to Xerostomia, Mucositis, & Dysphagia
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells.
- Conditions
- Dysphagia, Head and Neck Cancer, Mucositis, Xerostomia
- Trial name
- NCT00503776
- Testing
- exercise intervention, amifostine trihydrate, therapeutic dietary intervention
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Breast Cancer
S0430 Cyclophosphamide and Capecitabine in Treating Women With Stage IV Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00107276
- Testing
- capecitabine, cyclophosphamide
- Where
- 145 sites in United States
- Volunteers
- 112 people
- Sponsor
- SWOG Cancer Research Network
Breast Neoplasms
Study Evaluating HKI-272 in Tumors
The purpose of this study is to evaluate the safety and tolerability as well as find the maximum tolerated dose (MTD) for HKI-272.
- Trial name
- NCT00146172
- Testing
- neratinib
- Where
- 5 sites in United States
- Volunteers
- 73 people
- Sponsor
- Puma Biotechnology, Inc.
Myelofibrosis (MF)
Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis
Myelofibrosis is a type of bone marrow cancer that usually develops slowly and disrupts body's normal production of blood cells. It causes bone marrow scarring, leading to severe anemia that can cause weakness and fatigue.
- Trial name
- TRANSFORM-1 (NCT04472598)
- Testing
- Ruxolitinib, Navitoclax
- Where
- 194 sites in United States, Australia and 23 more
- Volunteers
- 252 people
- Sponsor
- AbbVie
Hemangioma
Clinical Trial of Vincristine vs. Prednisolone for Treatment of Complicated Hemangiomas
The goal of this study is to determine the safety and efficacy of Prednisolone and Vincristine for treatment of large, complicated infantile hemangiomas.
- Trial name
- NCT00555464
- Testing
- Vincristine, Prednisone
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Medical College of Wisconsin
Advanced, Metastatic
Study of ENMD-2076 in Patients With Advanced/Metastatic Soft Tissue Sarcoma
This is a phase 2 study of ENMD-2076 in patients with advanced/metastatic soft tissue sarcoma. This study will help to understand how well ENMD-2076 works and how safe and tolerable the drug is in this patient population.
- Conditions
- Advanced, Metastatic, Soft Tissue Sarcoma
- Trial name
- NCT01719744
- Testing
- ENMD-2076
- Where
- Canada
- Volunteers
- 25 people
- Sponsor
- University Health Network, Toronto
Advanced Nonhematological Malignancies
Study of Orally Administered TAK-960 in Patients With Advanced Nonhematologic Malignancies
Overview of Study Design: This is a phase 1, multicenter, open-label, multiple-dose, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of TAK-960 in patients with…
- Trial name
- NCT01179399
- Testing
- TAK-960
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Oral Contraceptive
Oral Contraceptive (OC) Estrogen Dose and Breast Proliferation
The purpose of this research study is to gain a better understanding of the changes that may occur in the breast when a woman uses an oral contraceptive (birth control pill).
- Trial name
- OCP2 (NCT01318005)
- Testing
- Oral Contraceptive: Ortho-Novum® 1/35, Oral Contraceptive: Ovcon® 35, Oral Contraceptive: Microgestin Fe® 1/20
- Where
- United States
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- University of Southern California
Hematologic Neoplasms, Neutropenia
The Relationship of Defeverscence and Itraconazole Plasma Level Study in Immunocompromised Participants
The purpose of this observational study is to investigate whether a sufficient concentration of itraconazole can influence disappearance of a fever (defeverscence) when intravenous (into the vein) itraconazole is administered for…
- Conditions
- Hematologic Neoplasms, Neutropenia, Fever
- Trial name
- NCT01021683
- Testing
- Itraconazole
- Volunteers
- 203 people
- Sponsor
- Janssen Korea, Ltd., Korea
Cancer, Pain
An Efficacy and Safety Study of Hydromorphone Hydrochloride (HCl) Oral Osmotic System (OROS) in the Reduction of Breakthrough Pain Medication Frequency in Participants With Cancer
The purpose of this study is to evaluate the clinical efficacy of hydromorphone hydrochloride (HCl) Oral Osmotic System (OROS) by assessing the extent of reduction of medication frequency for the management of breakthrough pain…
- Trial name
- NCT01006356
- Testing
- Hydromorphone HCl OROS
- Volunteers
- 141 people
- Sponsor
- Janssen Korea, Ltd., Korea
Colorectal Neoplasms
Trial Of Irinotecan In Combination With Three Methods Of Administration Of Fluoropyrimidine.
This study compares in the first study period combination of Irinotecan with three different methods of administration by Fluoropyrimidine. (ie. infusion, bolus and oral).
- Trial name
- NCT00101686
- Testing
- Modified Bolus 5-FU/LV with Irinotecan, FOLFIRI + bevacizumab, miFL + bevacizumab
- Where
- 175 sites in United States, Australia and 2 more
- Volunteers
- 547 people
- Sponsor
- Pfizer
Acute Leukemias
Study of Efficacy and Safety of LDE225 in Adult Patients With Relapsed/Refractory Acute Leukemia
The study will evaluate the efficacy, safety and tolerability of two dosing schedules of LDE225 in patients with relapsed/refractory acute leukemia or elderly patients with untreated acute leukemia.
- Trial name
- NCT01826214
- Testing
- LDE225
- Where
- 23 sites in United States, Australia and 9 more
- Volunteers
- 70 people
- Sponsor
- Novartis Pharmaceuticals
Cancer
VEG113971: An Open-Label Study of the Effects of Ketoconazole or Esomeprazole on Pazopanib PK
The purpose of this study is to determine how dosing with ketoconazole (Nizoral) or esomeprazole (Nexium) affects the pharmacokinetics of oral pazopanib.
- Trial name
- NCT01205230
- Testing
- pazopanib
- Where
- 2 sites in United States
- Volunteers
- 34 people
- Sponsor
- GlaxoSmithKline
Estrogen Receptor-negative Breast Cancer, Estrogen Receptor-positive Breast Cancer
Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery
This phase II trial studies how well giving combination chemotherapy and filgrastim together before surgery works in treating patients with human epidermal growth receptor 2 (HER2)-positive breast cancer that can be removed by…
- Conditions
- Estrogen Receptor-negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, HER2-positive Breast Cancer, Progesterone Receptor-negative Breast Cancer
- Trial name
- NCT00194779
- Testing
- doxorubicin hydrochloride, cyclophosphamide, paclitaxel
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Washington
Leukemia, Myeloid, Acute
A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy
The purpose of this study are 1. to determine the recommended combination dose of AG-120 and AG-221 separately when administered with azacitidine and, 2.
- Trial name
- NCT02677922
- Testing
- AG-120, Azacitidine, AG-221
- Where
- 49 sites in United States, Australia and 12 more
- Volunteers
- 130 people
- Sponsor
- Celgene
Adenocarcinoma, Pancreatic Neoplasms
VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors
This study is to evaluate the combination of an investigational drug X-82 with everolimus in the treatment of pancreatic neuroendocrine tumors.
- Trial name
- NCT01784861
- Testing
- X-82, Everolimus
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- Washington University School of Medicine
Acute Myeloid Leukemia
A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete Remission
The purpose of this study is to assess the efficacy and safety of oral azacitidine plus best supportive care versus best supportive care as maintenance therapy in a cohort of Japanese participants ≥ 55 years of age with Acute…
- Trial name
- NCT05197426
- Testing
- Oral Azacitidine
- Where
- 31 sites in United States, Japan
- Volunteers
- 19 people
- Sponsor
- Bristol-Myers Squibb